William S Gange1, Jennifer Lopez1, Benjamin Y Xu1, Khristina Lung2, Seth A Seabury1,2, Brian C Toy3. 1. Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA. 2. Keck-Shaeffer Initiative for Population Health Policy, Keck School of Medicine, University of Southern California, Los Angeles, CA. 3. Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA brian.toy@med.usc.edu.
Abstract
OBJECTIVE: To determine the incidence and risk factors for developing proliferative diabetic retinopathy (PDR), tractional retinal detachment (TRD), and neovascular glaucoma (NVG) at 5 years after the initial diagnosis of type 2 diabetes. RESEARCH DESIGN AND METHODS: Insured patients aged ≥18 years with newly diagnosed type 2 diabetes and 5 years of continuous enrollment were identified from a nationwide commercial claims database containing data from 2007 to 2015. The incidences of PDR, TRD, and NVG were computed at 5 years following the index diagnosis of type 2 diabetes. Associations between these outcomes and demographic, socioeconomic, and medical factors were tested with multivariable logistic regression. RESULTS: At 5 years following the initial diagnosis of type 2 diabetes, 1.74% (1,249 of 71,817) of patients had developed PDR, 0.25% of patients had developed TRD, and 0.14% of patients had developed NVG. Insulin use (odds ratio [OR] 3.59, 95% CI 3.16-4.08), maximum HbA1c >9% or >75 mmol/mol (OR 2.10, 95% CI 1.54-2.69), renal disease (OR 2.68, 95% CI 2.09-3.42), peripheral circulatory disorders (OR 1.88, 95% CI 1.25-2.83), neurological disease (OR 1.62, 95% CI 1.24-2.11), and older age (age 65-74 years) at diagnosis (OR 1.62, 95% CI 1.28-2.03) were identified as risk factors for development of PDR at 5 years. Young age (age 18-23 years) at diagnosis (OR 0.46, 95% CI 0.29-0.74), Medicare insurance (OR 0.60, 95% CI 0.70-0.76), morbid obesity (OR 0.72, 95% CI 0.59-0.87), and smoking (OR 0.84, 95% CI 0.70-1.00) were identified as protective factors. CONCLUSIONS: A subset of patients with type 2 diabetes develop PDR and other neovascular sequelae within the first 5 years following the diagnosis with type 2 diabetes. These patients may benefit from increased efforts for screening and early intervention.
OBJECTIVE: To determine the incidence and risk factors for developing proliferative diabetic retinopathy (PDR), tractional retinal detachment (TRD), and neovascular glaucoma (NVG) at 5 years after the initial diagnosis of type 2 diabetes. RESEARCH DESIGN AND METHODS: Insured patients aged ≥18 years with newly diagnosed type 2 diabetes and 5 years of continuous enrollment were identified from a nationwide commercial claims database containing data from 2007 to 2015. The incidences of PDR, TRD, and NVG were computed at 5 years following the index diagnosis of type 2 diabetes. Associations between these outcomes and demographic, socioeconomic, and medical factors were tested with multivariable logistic regression. RESULTS: At 5 years following the initial diagnosis of type 2 diabetes, 1.74% (1,249 of 71,817) of patients had developed PDR, 0.25% of patients had developed TRD, and 0.14% of patients had developed NVG. Insulin use (odds ratio [OR] 3.59, 95% CI 3.16-4.08), maximum HbA1c >9% or >75 mmol/mol (OR 2.10, 95% CI 1.54-2.69), renal disease (OR 2.68, 95% CI 2.09-3.42), peripheral circulatory disorders (OR 1.88, 95% CI 1.25-2.83), neurological disease (OR 1.62, 95% CI 1.24-2.11), and older age (age 65-74 years) at diagnosis (OR 1.62, 95% CI 1.28-2.03) were identified as risk factors for development of PDR at 5 years. Young age (age 18-23 years) at diagnosis (OR 0.46, 95% CI 0.29-0.74), Medicare insurance (OR 0.60, 95% CI 0.70-0.76), morbid obesity (OR 0.72, 95% CI 0.59-0.87), and smoking (OR 0.84, 95% CI 0.70-1.00) were identified as protective factors. CONCLUSIONS: A subset of patients with type 2 diabetes develop PDR and other neovascular sequelae within the first 5 years following the diagnosis with type 2 diabetes. These patients may benefit from increased efforts for screening and early intervention.
Authors: I M Stratton; E M Kohner; S J Aldington; R C Turner; R R Holman; S E Manley; D R Matthews Journal: Diabetologia Date: 2001-02 Impact factor: 10.122
Authors: Jennifer T Lloyd; Steve A Blackwell; Iris I Wei; Benjamin L Howell; William H Shrank Journal: Eval Health Prof Date: 2014-11-06 Impact factor: 2.651
Authors: Sherita H Golden; Chittaranjan Yajnik; Sanat Phatak; Robert L Hanson; William C Knowler Journal: Diabetologia Date: 2019-08-27 Impact factor: 10.122
Authors: Laurence Shen Lim; E Shyong Tai; Paul Mitchell; Jie Jin Wang; Wan Ting Tay; Ecosse Lamoureux; Tien Yin Wong Journal: Invest Ophthalmol Vis Sci Date: 2010-09 Impact factor: 4.799
Authors: Tien Y Wong; Jennifer Sun; Ryo Kawasaki; Paisan Ruamviboonsuk; Neeru Gupta; Van Charles Lansingh; Mauricio Maia; Wanjiku Mathenge; Sunil Moreker; Mahi M K Muqit; Serge Resnikoff; Juan Verdaguer; Peiquan Zhao; Frederick Ferris; Lloyd P Aiello; Hugh R Taylor Journal: Ophthalmology Date: 2018-05-24 Impact factor: 12.079
Authors: Kimberly D Brunisholz; Pascal Briot; Sharon Hamilton; Elizabeth A Joy; Michael Lomax; Nathan Barton; Ruthann Cunningham; Lucy A Savitz; Wayne Cannon Journal: J Multidiscip Healthc Date: 2014-11-21
Authors: Jennifer Lopez; William S Gange; Khristina Lung; Benjamin Y Xu; Seth A Seabury; Brian C Toy Journal: Diabetes Care Date: 2022-03-01 Impact factor: 19.112